Title |
CD 74 Directed Immunotherapy for B Cell Malignancies
|
Institution |
WEILL MEDICAL COLLEGE OF CORNELL UNIV, NEW YORK, NY
|
Principal Investigator |
LEONARD, JOHN
|
NCI Program Director |
William Merritt
|
Cancer Activity |
Clinical Oncology
|
Division |
DCTD
|
Funded Amount |
$327,262
|
Project Dates |
04/01/2007 - 03/31/2009
|
Fiscal Year |
2007
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Hematology (100.0%)
MOAB (100.0%)
|
Leukemia (50.0%)
Non Hodgkins lymphoma (50.0%)
|
Research Type |
Systemic Therapies - Clinical Applications
|
Abstract |
DESCRIPTION (provided by applicant): Non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are major causes of morbidity and mortality, with many patients not achieving cure. Monoclonal antibody-based therapies have been demonstrated to improve outcomes in some settings, and agents targeting novel antigens offer therapeutic promise. CD74 is widely expressed on B cell and other tumors, and has been associated with cellular proliferation and survival. The humanized anti-CD74 monoclonal antibody hLL1 has been evaluated in preclinical studies and demonstrated to induce a variety of anti-proliferative effects. We propose to evaluate this agent for potential therapeutic use in patients with B cell malignancies. Specifically, we plan to: Determine the phase I safety and activity (and establish a phase II dose) of the anti- CD74 humanized monoclonal antibody hLL1 in patients with recurrent NHL and CLL; Evaluate the in vivo biodistribution of Indium-111-labeled hLL1 in patients with B cell malignancies, and perform exploratory correlations with serum pharmacokinetics, tumor immunohistochemistry and lymphoma response. We anticipate that this project will provide important information regarding the potential utility of CD74-directed immunotherapy in B cell malignancies and possibly other tumor types, and will lead to further study of this approach on a broader scale which will hopefully improve outcomes for patients with these malignancies. |